Compare PDC & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDC | NSRX |
|---|---|---|
| Founded | 2018 | 2019 |
| Country | Japan | Israel |
| Employees | 20 | 7 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.7M | 25.8M |
| IPO Year | N/A | N/A |
| Metric | PDC | NSRX |
|---|---|---|
| Price | $7.10 | $2.79 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | ★ 130.1K | 126.7K |
| Earning Date | 07-01-2026 | 03-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.46 | $1.98 |
| 52 Week High | $8.40 | $9.99 |
| Indicator | PDC | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.62 | 43.62 |
| Support Level | $4.48 | $2.41 |
| Resistance Level | $7.90 | $3.48 |
| Average True Range (ATR) | 0.77 | 0.28 |
| MACD | -0.20 | -0.02 |
| Stochastic Oscillator | 39.31 | 9.89 |
Earlyworks Co Ltd is a blockchain-based technology company. It builds products, delivers services, and develops solutions based on a proprietary grid ledger system to leverage blockchain technology in various business settings, including advertisement tracking, online visitor management, and sales of non-fungible tokens. The company's customers represent a diverse range of industries, such as information technology, shipping, real estate, entertainment, cosmetics, and chemical products.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.